Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

GlobalData analyst Vasilis Roumpelakis notes that bispecifics could hold strong potential in the future, but manufacturing ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetesIf approved, Tzield would be the first ...

Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substantial investment in traditional patient support ...

The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 ...

If you are wondering whether Sanofi shares around €82.29 offer good value today, you are not alone. This article is designed to help you frame that question clearly. The stock has had a mixed run, ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...

Five undervalued stocks including CleanSpark, Sanofi, Uber, Macy's and e.l.f. Beauty combine discounted valuations with strong analyst buy ratings for 2026.